相关实验视频

Updated: May 17, 2025

Use of Artificial Sputum Medium to Test Antibiotic Efficacy Against Pseudomonas aeruginosa in Conditions More Relevant to the Cystic Fibrosis Lung

Use of Artificial Sputum Medium to Test Antibiotic Efficacy Against Pseudomonas aeruginosa in Conditions More Relevant to the Cystic Fibrosis Lung

Published on: June 5, 2012

在现实研究中,N-乙半氨酸对支气管切除的作用. 来自西班牙RIBRON注册表的数据

Grace Oscullo¹, Raúl Méndez¹, Casilda Olveira²

¹Servicio de Neumología e Instituto de Investigación La Fe (IISLAFE), Hospital Universitario y Politécnico La Fe, Valencia, Spain; Centro de Investigación Biomédica en Red de Enfermedades Respiratorias, Instituto de Salud Carlos III, Madrid, Spain.

Archivos de bronconeumologia

|April 3, 2025

概括

N-乙半氨酸 (N-AC) 显著减少支气管切除症患者的恶化,住院和唾液. 这种粘菌药物是安全有效的,改善了生活质量,减少了Pseudomonas aeruginosa感染.

科学领域:

肺部病理学肺部病理学
药理学药理学是指药理学的学科.
临床医学临床医学

背景情况:

有限的数据存在于N-乙半氨酸 (N-AC) 在支气管病的使用.
N-AC 是一种常用的粘菌解毒剂.

研究的目的:

分析N-AC对支气管切除症患者关键结局的影响.
评估N-AC在减少恶化,住院和产生的有效性.

主要方法:

这是一项雄心勃勃的,纵向的,多中心的观察性研究,涉及2461名成年支气管切除症患者.
在6个月内接受至少600mg/dN-AC的患者与未接受N-AC的患者之间的比较.
使用ANCOVA对治疗前两年和治疗后两年变量进行分析,对共同变量进行调整.

主要成果:

在N-AC组,恶化病例减少了27%,住院病例减少了17%.
唾液产生 (59.7%) 和Pseudomonas aeruginosa隔离 (12%) 的显著下降.
600mg/d的N-AC在恶化率方面表现出与1200mg/d相似的疗效.

结论:

N-乙半氨酸 (N-AC),通常在600mg/d,是安全和有效的支气管切除.
N-AC可以减少恶化,住院,液/体积以及Pseudomonas aeruginosa的隔离.
该药物耐受性良好,是治疗支气管病的有价值的治疗选择.

关键词:

支气管切除症是一种支气管切除症.恶化的情况加剧.住院治疗住院治疗死亡率死亡率死亡率伪omonas aeruginosa 这种类型的病毒.

更多相关视频

Long Term Chronic Pseudomonas aeruginosa Airway Infection in Mice

Long Term Chronic Pseudomonas aeruginosa Airway Infection in Mice

Published on: March 17, 2014

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

相关概念视频

Acute Respiratory Failure-V

Acute Respiratory Failure-V

The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...

COPD: Management Using Bronchodilators and Corticosteroids

COPD: Management Using Bronchodilators and Corticosteroids

Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...